Related Experiment Videos
Treatment of systemic sclerosis
1University of Western Ontario, London, Canada.
Abstract:
Although there have been no major breakthroughs in scleroderma therapy, new treatments have been tested in patients with systemic sclerosis, including both interferon alfa and interferon gamma. These biologic agents can reduce collagen synthesis, which is a rational target for scleroderma therapy. Debate about the use of photopheresis continues, and it was suggested in a recent editorial that photopheresis is no better than D-penicillamine in the treatment of scleroderma and is more expensive. Cyclosporine appears to have frequent renal toxicity when used to treat scleroderma. Outcome measurements have been concentrated on in scleroderma trials. Several types of scleroderma classifications were compared, and the classification of diffuse and limited scleroderma was strongly related to disease severity. Skin score was systematically compared with mapping the surface area of involved skin, and the skin score was found to be more reliable. A possible prognostic indicator in scleroderma is high-resolution pulmonary computed tomography, which is sensitive in early detection of scleroderma-associated interstitial lung disease. Classification of Raynaud's phenomenon into primary and secondary forms has been proposed, and further testing of the criteria and long-term follow-up is necessary to validate this classification. Over the past year, treatment of vasospasm with prostacyclin analogues has been efficacious with iloprost but not with low-dose oral cicaprost. Tissue plasminogen activator is not beneficial in the treatment of Raynaud's phenomenon. A report of radical microarteriolysis for the treatment of refractory Raynaud's phenomenon seems promising, warranting further investigation.
Insights
New biologic agents show promise for systemic sclerosis by targeting collagen synthesis. Research also focuses on reliable outcome measures and early detection of lung disease in scleroderma patients.
Area of Science:
- Rheumatology
- Dermatology
- Pulmonology
Background:
- Scleroderma, or systemic sclerosis, lacks major therapeutic breakthroughs.
- New treatments are being investigated, including biologic agents and novel approaches to managing complications like Raynaud's phenomenon.
Purpose of the Study:
- To review recent advancements and ongoing research in scleroderma therapy and outcome measurement.
- To evaluate the efficacy and safety of emerging treatments for systemic sclerosis and its associated conditions.
Main Methods:
- Review of recent studies and clinical trials concerning scleroderma treatments.
- Comparison of different scleroderma classification systems and outcome measurement tools.
- Evaluation of treatments for systemic sclerosis, Raynaud's phenomenon, and interstitial lung disease.
Main Results:
- Interferon alfa and gamma show potential by reducing collagen synthesis.
- Photopheresis efficacy is debated; cyclosporine use is limited by renal toxicity.
- Diffuse and limited scleroderma classification correlates with disease severity; skin score is a reliable measure.
- High-resolution pulmonary CT aids early detection of lung disease.
- Iloprost is effective for vasospasm, but not all prostacyclin analogues.
- Radical microarteriolysis shows promise for refractory Raynaud's phenomenon.
Conclusions:
- While no major breakthroughs exist, ongoing research explores promising therapeutic targets like collagen synthesis.
- Standardized outcome measurements and reliable classification systems are crucial for scleroderma research.
- Early detection and management of complications, such as interstitial lung disease and Raynaud's phenomenon, are vital.